We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
Invitation Homes
INVH
$17.6B
| $1.03M | 0.01% |
+34,667
| New | +$976K |
|
577
NetApp
NTAP
$33.3B
| $1.02M | 0.01% |
19,389
-13,768
| -42% | -$738K |
|
|
CIT
578
DELISTED
CIT Group Inc.
CIT
| $1.01M | 0.01% |
22,361
-1,529
| -6% | -$71.3K |
|
579
Cboe Global Markets
CBOE
$30.2B
| $1.01M | 0.01% |
8,801
+1,688
| +24% | +$195K |
|
580
NOV
NOV
$7.35B
| $1.01M | 0.01% |
47,577
+43
| +0.1% | +$917 |
|
|
SRCI
581
DELISTED
SRC Energy Inc
SRCI
| $1.01M | 0.01% |
+216,032
| New | +$976K |
|
582
STAAR Surgical
STAA
$1.14B
| $1M | 0.01% |
39,000
| – | – |
|
583
Teleflex
TFX
$5.8B
| $1M | 0.01% |
+2,957
| New | +$1.03M |
|
|
KSU
584
DELISTED
Kansas City Southern
KSU
| $996K | 0.01% |
7,488
-826
| -10% | -$103K |
|
585
Hawaiian Electric Industries
HE
$2.28B
| $988K | 0.01% |
21,657
+1,674
| +8% | +$74.4K |
|
586
NNN REIT
NNN
$9.36B
| $984K | 0.01% |
+17,442
| New | +$949K |
|
587
Twilio
TWLO
$29.5B
| $983K | 0.01% |
+8,944
| New | +$1.16M |
|
588
Fox Class A
FOXA
$23.8B
| $982K | 0.01% |
31,128
-10,051
| -24% | -$348K |
|
|
WUBA
589
DELISTED
58.com Inc
WUBA
| $981K | 0.01% |
11,400
+400
| +4% | +$22.1K |
|
590
United Rentals
URI
$70.2B
| $979K | 0.01% |
7,857
+150
| +2% | +$18.2K |
|
591
Elanco Animal Health
ELAN
$12.7B
| $975K | 0.01% |
36,680
+11,900
| +48% | +$357K |
|
|
AIV
592
Aimco
AIV
$377M
| $968K | 0.01% |
139,334
-232,636
| -63% | -$1.58M |
|
593
iRhythm Holdings
IRTC
$3.69B
| $963K | 0.01% |
+13,000
| New | +$1.01M |
|
|
VG
594
DELISTED
Vonage Holdings Corporation
VG
| $956K | 0.01% |
+57,300
| New | +$728K |
|
595
FMC
FMC
$1.39B
| $954K | 0.01% |
10,882
| – | – |
|
|
LSXMK
596
DELISTED
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
| $941K | 0.01% |
29,459
+3,192
| +12% | +$99.2K |
|
597
HEICO Corp Class A
HEI.A
$36.3B
| $935K | 0.01% |
+9,608
| New | +$1.02M |
|
598
Marvell Technology
MRVL
$170B
| $929K | 0.01% |
37,188
+358
| +1% | +$8.98K |
|
|
JNPR
599
DELISTED
Juniper Networks
JNPR
| $915K | 0.01% |
36,986
-44,468
| -55% | -$1.12M |
|
600
Henry Schein
HSIC
$9.64B
| $914K | 0.01% |
14,401
+1,858
| +15% | +$120K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.